Ant Insurance Uses AI to Help Partner Insurers Process 7.25 Million Health Claims in 2024, Up 55% YoY
In 2024, leading insurers in China processed 7.25 million health claims through Ant Insurance, Ant Group's online insurance brokerage platform, marking a 55% year-over-year increase. Total health claim payouts on the platform reached RMB 9.2 billion (USD 1.3 billion). This growth is driven by ongoing innovations in product offerings and user experience, which build trust and meet user needs, while also reflecting the increasing demand for health insurance services.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250309812706/en/
Partner insurers processed 7.25 million health claims through Ant Insurance in 2024, up 55% year-over-year. (Photo: Business Wire)
The trend is expected to accelerate as China’s demographic patterns shift. By around 2035, over 400 million people, or more than 30% of the population, will be aged 60 or older, according to projections from China’s National Health Commission. As healthcare needs expand, commercial health insurance is becoming an essential complement to the country's basic medical system.
Ant Group has been leveraging innovative technologies to drive the digital transformation of the healthcare sector, with health insurance playing a key role.
Early in 2018, Ant Insurance introduced Haoyibao, a flagship health insurance product developed in partnership with leading insurers in China. It was the first in the country to offer guaranteed renewal for six consecutive years with payouts of up to RMB 4 million (USD 550,000). Over time, Haoyibao has been continually upgraded to support a wider range of people and health conditions. As a bestselling product, it has helped millions of families manage the financial burden of medical expenses.
With technologies like AI, Ant Insurance has streamlined every step of the insurance process - from product selection and planning to management and claims - making insurance services more accessible to the public.
The GoldenChoice feature uses the Ant Insurance Multi-factor Model (AIMM) to compare and select the best insurance products. Meanwhile, the EasyPick AI insurance planner creates personalized plans for users, helping them avoid overbuying or selecting the wrong coverage. In 2024, the AI-powered EasyClaims solution helped 11 partner insurers streamline the claims process for over 85 health insurance products, with AI handling 96% of the 1.62 million claims analysis requests from policyholders.
Further enhancing insurer capabilities, Ant Insurance launched Ant Bridge in September 2024. This open platform integrates AI models and financial intelligence to help insurers provide real-time, personalized responses to customer inquiries, improving service quality and operational efficiency.
Beyond insurance, Ant Group has been actively contributing to the digital transformation of China’s healthcare industry for over a decade. Since launching the country’s first online hospital appointment booking service in 2014, Ant Group’s Alipay digital platform has been assisting hospitals in developing digital services. As of January 2025, Alipay has connected more than 800 million users with services from over 3,600 hospitals.
In September 2024, Ant Group introduced the AI Healthcare Manager within the Alipay app. Available through voice and text interactions, this tool provides users with access to over 30 services, including doctor mapping, medical report interpretation, in-hospital navigation, and personalized medical advice.
Through these ongoing initiatives, Ant Group is contributing to the more efficient use of limited medical resources, with the aim of supporting greater medical inclusion.
About Ant Group
Ant Group aims to build the infrastructure and platforms to support the digital transformation of the service industry. Through continuous innovation, we strive to provide all consumers and small and micro businesses equal access to digital financial and other daily life services that are convenient, sustainable and inclusive.
For more information, please visit our website at www.antgroup.com or follow us on Twitter @AntGroup.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250309812706/en/
Contacts
Media Inquiries
Yinan Duan
duanyinan.dyn@antgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA ™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 14:00:00 EEST | Press release
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the durable benefit that vimseltinib can offer patients.” Summary of Data and Findings from the 2-year results of the MOTION Phase
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 17:09:00 EEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 17:00:00 EEST | Press release
Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the study increased considerably to 76.2% (95% CI: 63.8, 86.0) by blinded independent review committee (BICR) per RECIST v1.1, from 54% at Week 25. The study also showed continued clinically meaningful improvements in key secondary endpoints related to patient outcomes such as pain and function. The safety profile was consistent with previously reported data. The results are being presented today in the Sarcoma mini-oral session at the European Society for Medical
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 16:04:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B cell-mediated diseases. Pove is the only BAFF+APRIL inhibitor in pivotal trials for multiple kidney diseases. Next Steps for Pove Development In IgAN Following the announcement that the Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to pove for the treatment of IgAN, FDA recently granted a rolling review of the Biologics License Application (BLA) for pove for this indication. Vertex expects to submit the first module to FDA for potential accelerated approval before t
Qualcomm Announces Quarterly Cash Dividend17.10.2025 16:00:00 EEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom